Understanding Dry Age-Related Macular Degeneration: A Comprehensive Overview
Dry AMD, a common ocular condition affecting individuals over 50, leads to a gradual decline in central vision due to macular thinning. The macula, essential for sharp central vision, is affected, causing symptoms like difficulty seeing in low light, distorted straight lines, and altered color perception.
Prevalence and Geographic Distribution
In 2023, the United States had the highest prevalence of dry AMD among the 7MM (United States, European Union 4, Japan, and China). Asian countries generally have a lower prevalence of geographic atrophy, a late-stage form of dry AMD.
Current Treatment Landscape
There are currently no approved treatments for intermediate AMD, highlighting a significant unmet need. Dietary vitamins and lifestyle modifications are recommended to manage this stage. Geographic atrophy, however, has two recently FDA-approved therapies, IZERVAY and SYFOVRE, which aim to slow disease progression.
Emerging Therapies and Market Outlook
The dry AMD market is expected to expand in the coming years, with a strong pipeline of peptide derivatives, antibodies, and gene therapies. These therapies target different mechanisms, offering hope for improved efficacy and treatment outcomes. The introduction of therapies with enhanced efficacy and a broader target population is expected to drive market growth.
Challenges and Growth Potential
Despite the promising advances, there are challenges that could impact market growth. Slow progress in clinical trials, high anticipated costs of emerging gene therapies and stem cell therapies, and limited awareness about the disease may hinder market expansion. Nevertheless, the unmet need for effective treatments and the potential for innovative therapies continue to offer opportunities for growth.
DelveInsight’s Comprehensive Report
DelveInsight’s report provides detailed insights into the dry AMD market, including pipeline analysis, epidemiology, market size, and key players. This comprehensive information supports informed decision-making for pharmaceutical companies, researchers, and healthcare professionals in the field of ophthalmology.
